

Hessam Kakavand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9589790/publications.pdf>

Version: 2024-02-01

8
papers

880
citations

1163117
8
h-index

1588992
8
g-index

9
all docs

9
docs citations

9
times ranked

1760
citing authors

#	ARTICLE	IF	CITATIONS
1	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 131-141.	3.4	55
2	Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 249-259.	2.6	33
3	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	2.8	150
4	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1620.	7.4	515
5	Pharmacologic Prevention of Myocardial Ischemia-Related Reperfusion Injury in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 430-449.	1.9	12
6	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3080-3089.	3.8	13
7	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	2.8	42
8	Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 359-367.	1.9	53